50 results about "Locally advanced" patented technology

A catheter system adapted for navigating, guiding and implanting a catheter or a plurality of catheters in a spatially-defined implantation within the tissue of a patient is provided. The system can include a tissue navigation system and a probe to inform the navigation system to guide emplacement of the catheters within a target tissue. The probe can provide images, such as fiberoptic visual images, or ultrasound images, or can provide radiolocation data, to guide the catheter emplacement. The catheters supply a pressurized liquid including a bioactive agent, such as can be used in the treatment of cancer, for example 123I- or 125I-IUDR. The system and methods provided can be used in the treatment of locally advanced tumors, such as cancers of the brain, head or neck, esophagus, prostate, ovary, liver, pancreas, bladder or rectum.

The invention provides methods and dosing regimens for treating metastatic stage prostate cancer in a subject using degarelix, as well as related methods of using degarelix in a subject identified as having metastatic stage prostate cancer, and methods of using degarelix to prevent or delay the progression of locally advanced prostate cancer.

Provided herein are methods, compositions and kits for the treatment of locally advanced or metastatic breast cancer or breast cancer brain metastases. The method comprises administration of 4-iodo-3-nitrobenzamide, a metabolite or salt thereof in combination with irinotecan. The method of treating locally advanced or metastatic breast cancer comprises at least one 21 day treatment cycle.

Methods of treating patients having HER2-positive, operable, locally advanced or inflammatory breast cancer with the antibody-drug conjugate Trastuzumab-MCC-DM1 and Pertuzumab are provided.

Provided herein are methods of treating, preventing and/or managing locally advanced breast cancer, including inflammatory breast cancer, which comprise administering to a patient one or more immunomodulatory compounds or enantiomers or mixtures of enantiomers thereof, or pharmaceutically acceptable salts, solvates, hydrates, co-crystals, clathrates, or polymorphs thereof.

A catheter array system adapted for implanting a plurality of catheters within the tissue of a patient in a spatially defined array, comprising a plurality of catheters, a catheter guide template adapted to guide the implantation of catheters, and a liquid supply system including a pressurizer and a manifold, is provided. A method of treatment of a malcondition in a patient comprises implantation of a spatially definted array of catheters using the system is also provided. The bioactive agent can be a radiotherapeutic agent, a chemotherapeutic agent, a protein, an antibody, an oligonucleotide-based therapeutic agent such as siRNA, or a combination of agents. A preferred radiotherapeutic agent is ¹²³I- or ¹²⁵I-IUDR, for example in the treatment of locally advanced tumors, such as glioblastoma multiforme.

The preparation of crystalline Erlotinib base form G2 is described. This crystalline form can be converted to an Erlotinib salt, such as Erlotinib HCl, which can be used in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

The present invention relates to a novel system for predicting a prognosis capable of predicting the prognosis of locally advanced gastric cancer, and more specifically, capable of predicting a clinical result after a resection during gastric cancer surgery through gene set enrichment comparative analysis.

A method and apparatus that increases safety when employing externally focused adaptive phased array microwave thermotherapy (hyperthermia) for breast cancer treatment include microwave absorbing pads and metallic shielding to prevent undesired or stray surface tissue heating and to cushion the breast from mechanical pressure during breast compression. The microwave absorbing pads are attached on the top of the microwave waveguide thermotherapy applicators and on top of the breast compression paddles. A metallic-shielding strip mounted across the top portion of the microwave applicator aperture acts to block microwave radiation from illuminating the base of the breast and chest wall area. The patient treatment table utilizes a metallic shield to shield the body from stray microwave radiation. Treatments incorporating the safety improvements include thermotherapy for early-stage breast carcinomas, locally advanced breast cancer, ductal carcinoma in-situ, and benign breast lesions.

The invention provides methods of treating breast cancer in subjects having locally advanced or metastatic breast cancer.

The invention relates to a preparation method for a micro-molecular kinase inhibitor. Specifically, the invention discloses a novel method for preparing the micro-molecular kinase inhibitor capable of treating locally-advanced or metastatic non-small cell lung cancer (NSCLC) with positive anaplastic lymphoma kinase (ALK). The method comprises the following steps: with a compound (II) as a starting material, carrying out a substitution reaction, a reduction reaction, an oxidation reaction, a cyclization reaction and a reduction and deprotection reaction so as to form crizotinib as shown in a formula (I) in the specification. The method provided by the invention has the advantages of environment-friendly synthetic route, simple and safe operation, high overall yield, good economic benefits, and facilitation industrial production.

The present disclosure provides methods and kits for using biomarkers for predicting treatment response, determining likely survival rate, and/or determining aggressiveness of conditions such as Locally Advanced Breast Cancer (LABC) and Inflammatory Breast Cancer (IBC) in a subject.

The invention provides a traditional Chinese medicine composition and an application thereof in preparation of medicines which are used in three-dimensional conformal and intensity modulated radiation therapy for treating advanced pancreatic carcinomas and have synergistic sensitizing and pain relieving effects. The traditional Chinese medicine composition comprises compound Danshen root injection and Qingyi Huaji formula granules. The radiosensitivity of pancreatic carcinomas can be obviously improved, the proliferation inhibition effects on pancreatic carcinomas can be improved and the pains of patients can be relieved by applying the traditional Chinese medicine composition seven days before radiation therapy or while radiation therapy.

The present invention relates to a method for determining or predicting the response of a patient diagnosed with locally advanced rectal cancer to chemoradiotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with rectal cancer to specific medicaments, radiotherapy and/or chemotherapy. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles in samples of said patients.

Although tumor-associated macrophages have been extensively studied in the control of response to radiotherapy, the molecular mechanisms involved in the ionizing radiation-mediated activation of macrophages remain elusive. Here the present inventors show that ionizing radiation induces the expression of interferon-regulatory factor 5 (IRF5) promoting thus macrophage activation toward a pro-inflammatory phenotype. They reveal that the activation of the Ataxia telangiectasia mutated (ATM) kinase is required for ionizing radiation-elicited macrophage activation, but also for macrophage reprogramming after treatments with γ-interferon, lipopolysaccharide or chemotherapeutic agent (such as cis-platin), underscoring the fact that the kinase ATM plays a central role during macrophage phenotypic switching toward a proinflammatory phenotype. They further demonstrate that NADPH oxidase 2 (NOX2)-dependent ROS production is upstream to ATM activation and is essential during this process. They also report that hypoxic conditions and the inhibition of any component of this signaling pathway (NOX2, ROS and ATM) impairs pro-inflammatory activation of macrophages and predicts a poor tumor response to preoperative radiotherapy in locally advanced rectal cancer. Altogether, these results identify a novel signaling pathway involved in macrophage activation that may enhance effectiveness of radiotherapy through the re-programming of tumor infiltrating macrophages.

This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma in patients in need thereof.

A method of treating patients suffering from carcinoma of intrahepatic or extra hepatic bile duct or gall bladder which is locally advanced or metastatic, by intravenously administering to the patient, paclitaxel in the form of a nanodispersion. The nanodispersion comprises particles with a mean particle size less than 300 nm and is free of polyoxyethylated castor oil and free of a protein.